BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38151076)

  • 1. Larixol is not an inhibitor of Gα
    Björkman L; Forsman H; Bergqvist L; Dahlgren C; Sundqvist M
    Biochem Pharmacol; 2024 Feb; 220():115995. PubMed ID: 38151076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PAR4-derived pepducin P4Pal
    Holdfeldt A; Lind S; Hesse C; Dahlgren C; Forsman H
    Biochem Pharmacol; 2020 Oct; 180():114143. PubMed ID: 32653592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils.
    Liao HR; Kao YY; Leu YL; Liu FC; Tseng CP
    Biochem Pharmacol; 2022 Jul; 201():115091. PubMed ID: 35569521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of Gαi-coupled formyl peptide receptors is inhibited by Gαq-selective inhibitors when induced by signals generated by the platelet-activating factor receptor.
    Holdfeldt A; Dahlstrand Rudin A; Gabl M; Rajabkhani Z; König GM; Kostenis E; Dahlgren C; Forsman H
    J Leukoc Biol; 2017 Sep; 102(3):871-880. PubMed ID: 28760822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZ2158 is a more potent formyl peptide receptor 1 inhibitor than the commonly used peptide antagonists in abolishing neutrophil chemotaxis.
    Forsman H; Wu Y; Mårtensson J; Björkman L; Granberg KL; Dahlgren C; Sundqvist M
    Biochem Pharmacol; 2023 May; 211():115529. PubMed ID: 37004778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Larixol is not an inhibitor of Gα
    Björkman L; Forsman H; Bergqvist L; Dahlgren C; Sundqvist M
    Biochem Pharmacol; 2023 Nov; ():115919. PubMed ID: 37952896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
    Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
    J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Two Formyl Peptide Receptors Differently Regulate GPR84-Mediated Neutrophil NADPH Oxidase Activity.
    Mårtensson J; Sundqvist M; Manandhar A; Ieremias L; Zhang L; Ulven T; Xie X; Björkman L; Forsman H
    J Innate Immun; 2021; 13(4):242-256. PubMed ID: 33789297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead.
    Winther M; Gabl M; Welin A; Dahlgren C; Forsman H
    FEBS Lett; 2015 Jul; 589(15):1832-9. PubMed ID: 26071379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
    Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
    Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
    Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
    J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
    Lind S; Dahlgren C; Holmdahl R; Olofsson P; Forsman H
    J Leukoc Biol; 2021 Jun; 109(6):1105-1120. PubMed ID: 33040403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Garcinia Multiflora Inhibits FPR1-Mediated Neutrophil Activation and Protects Against Acute Lung Injury.
    Tsai YF; Yang SC; Chang WY; Chen JJ; Chen CY; Chang SH; Hwang TL
    Cell Physiol Biochem; 2018; 51(6):2776-2793. PubMed ID: 30562761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question.
    Winther M; Holdfeldt A; Sundqvist M; Rajabkhani Z; Gabl M; Bylund J; Dahlgren C; Forsman H
    PLoS One; 2017; 12(9):e0185132. PubMed ID: 28934373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1.
    Yang SC; Chung PJ; Ho CM; Kuo CY; Hung MF; Huang YT; Chang WY; Chang YW; Chan KH; Hwang TL
    J Immunol; 2013 Jun; 190(12):6511-9. PubMed ID: 23670191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library.
    Forsman H; Kalderén C; Nordin A; Nordling E; Jensen AJ; Dahlgren C
    Biochem Pharmacol; 2011 Feb; 81(3):402-11. PubMed ID: 21095183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
    Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
    Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
    Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
    Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
    Forsman H; Dahlgren C
    Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pepducin derived from the third intracellular loop of FPR2 is a partial agonist for direct activation of this receptor in neutrophils but a full agonist for cross-talk triggered reactivation of FPR2.
    Gabl M; Winther M; Skovbakke SL; Bylund J; Dahlgren C; Forsman H
    PLoS One; 2014; 9(10):e109516. PubMed ID: 25303226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.